Stocktoria
Solid Biosciences Inc. SLDB
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-01-26
Solid Biosciences Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | — | — | — | -1315.2% | -530.5% | — | — | — | — |
| FCF margin | — | — | — | -1247.7% | -580.4% | — | — | — | — |
| Return on assets | — | — | — | — | — | — | -113.3% | -53.6% | -68.4% |
| Return on equity | — | — | — | — | — | — | -146.4% | -59.8% | 88.0% |
| Current ratio | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 | 6.49 | 4.72 | 10.31 | 6.27 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.